West Pharmaceutical Services Inc (NYSE: WST), a provider of injectable drug administration solutions, announced on Monday that it has entered into a definitive agreement to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, together with associated facilities, to pharmaceutical company AbbVie (NYSE: ABBV) for total consideration of USD112.5m at close, subject to working capital and other customary adjustments. The transaction is subject to closing conditions and is expected to complete in mid-2026.

West will continue commercial supply of the SmartDose 3.5mL system and execute critical project commitments prior to completion, including potential milestone-based payments before closing. SmartDose 3.5mL revenues are expected to account for around 4% of fiscal year 2025 revenues, with further detail to be provided alongside 2026 guidance during the fourth quarter 2025 earnings call in February.

Development and manufacture of other SmartDose platforms will continue, including the SmartDose 10mL On-Body Delivery System and adaptive technologies for larger-volume delivery.